Therma Bright Investment Portfolio Company InStatin Secures Mountain West Research Discovery Study Agreement
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) announces that its investment portfolio company, InStatin, has secured an agreement with Mountain West Research for a non-GLP discovery study. This study will investigate the pharmacokinetics of InStatin's innovative statin inhalant solution for asthma and COPD treatment.
The research aims to provide insights for targeting the delivery of active pharmaceutical ingredients (API) in the lungs, supporting the development of InStatin's therapeutic solution. This pre-clinical study is a important step towards Phase 1 human trials.
Therma Bright owns 17% of InStatin, with potential for increased ownership through a SAFE investment. The Asthma Treatment market is projected to reach USD 39.04 billion by 2032, growing at a CAGR of 3.8% from 2023 to 2032.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) annuncia che la sua società in portafoglio di investimenti, InStatin, ha stipulato un accordo con Mountain West Research per uno studio di scoperta non-GLP. Questo studio esplorerà la farmacocinetica della soluzione innovativa di statina inalante di InStatin per il trattamento dell'asma e della BPCO.
La ricerca mira a fornire spunti per la somministrazione degli ingredienti attivi farmaceutici (API) nei polmoni, sostenendo lo sviluppo della soluzione terapeutica di InStatin. Questo studio preclinico rappresenta un passo importante verso i trial clinici di Fase 1.
Therma Bright possiede il 17% di InStatin, con possibilità di aumentare la partecipazione attraverso un investimento SAFE. Si prevede che il mercato del trattamento dell'asma raggiunga 39,04 miliardi di USD entro il 2032, con una crescita annuale composta (CAGR) del 3,8% dal 2023 al 2032.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) anuncia que su empresa de cartera de inversiones, InStatin, ha asegurado un acuerdo con Mountain West Research para un estudio de descubrimiento no-GLP. Este estudio investigará la farmacocinética de la innovadora solución inhalante de estatinas de InStatin para el tratamiento del asma y EPOC.
La investigación busca proporcionar información para dirigir la entrega de ingredientes farmacéuticos activos (API) en los pulmones, apoyando el desarrollo de la solución terapéutica de InStatin. Este estudio preclínico es un paso importante hacia los ensayos clínicos en Fase 1.
Therma Bright posee el 17% de InStatin, con potencial para aumentar la propiedad a través de una inversión SAFE. Se proyecta que el mercado del tratamiento del asma alcance 39,04 mil millones de USD para 2032, creciendo a una tasa compuesta anual (CAGR) del 3,8% desde 2023 hasta 2032.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF)는 투자 포트폴리오 회사인 InStatin이 Mountain West Research와 비-GLP 탐사 연구에 대한 계약을 체결했다고 발표했습니다. 이 연구는 인스타틴의 혁신적인 흡입형 스타틴 솔루션의 약물 동태학을 조사할 것입니다. 이는 천식 및 COPD 치료에 사용됩니다.
이 연구는 폐에서 활성 제약 성분(API)의 전달을 타겟팅하는 데 대한 통찰력을 제공하여 인스타틴의 치료 솔루션 개발을 지원할 것입니다. 이 전임상 연구는 1상 인간 임상 시험을 향한 중요한 단계입니다.
Therma Bright는 InStatin의 17%를 소유하고 있으며, SAFE 투자를 통해 소유권 증가의 잠재력이 있습니다. 천식 치료 시장은 2032년까지 390억 4천만 달러에 이를 것으로 예상되며, 2023년부터 2032년까지 연평균 성장률(CAGR) 3.8%로 성장할 것입니다.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) annonce que sa société de portefeuille, InStatin, a conclu un accord avec Mountain West Research pour une étude de découverte non-GLP. Cette étude examinera la pharmacocinétique de la solution inhalante innovante de statine d'InStatin pour le traitement de l'asthme et de la BPCO.
La recherche vise à fournir des aperçus pour cibler la livraison des ingrédients actifs pharmaceutiques (API) dans les poumons, soutenant le développement de la solution thérapeutique d'InStatin. Cette étude préclinique est une étape importante vers les essais cliniques de Phase 1.
Therma Bright possède 17 % d'InStatin, avec un potentiel d'augmentation de la propriété grâce à un investissement SAFE. Le marché du traitement de l'asthme devrait atteindre 39,04 milliards USD d'ici 2032, avec un taux de croissance annuel composé (CAGR) de 3,8 % entre 2023 et 2032.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) gibt bekannt, dass ihr Portfolio-Unternehmen InStatin eine Vereinbarung mit Mountain West Research für eine nicht-GLP Entdeckungsstudie gesichert hat. Diese Studie wird die Pharmakokinetik der innovativen inhalativen Statinlösung von InStatin für die Behandlung von Asthma und COPD untersuchen.
Die Forschung zielt darauf ab, Einblicke in die gezielte Verabreichung aktiver pharmazeutischer Inhaltsstoffe (API) in die Lunge zu geben und die Entwicklung der therapeutischen Lösung von InStatin zu unterstützen. Diese präklinische Studie ist ein wichtiger Schritt in Richtung der Phase-1-Menschenversuche.
Therma Bright besitzt 17% von InStatin und hat das Potenzial, die Beteiligung durch eine SAFE-Investition zu erhöhen. Der Asthmabehandlungsmarkt wird bis 2032 voraussichtlich 39,04 Milliarden USD erreichen und wächst von 2023 bis 2032 mit einer jährlichen Wachstumsrate (CAGR) von 3,8%.
- InStatin secures agreement with Mountain West Research for a pre-clinical discovery study
- Study aims to enhance efficacy and bioavailability of InStatin's asthma and COPD treatment
- Research supports preparation for Phase 1 human trials
- Therma Bright owns 17% of InStatin with potential for increased ownership
- Asthma Treatment market projected to reach USD 39.04 billion by 2032, growing at 3.8% CAGR
- None.
Clinical research will offer insight for specific targeting of active pharmaceutical ingredients (API) that will further support Phase 1 Human Trials.
Toronto, Ontario--(Newsfile Corp. - September 23, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in cutting-edge diagnostic and medical device technologies, extends its congratulations to strategic investment portfolio company InStatin on its recent agreement with Mountain West Research to conduct a comprehensive non-GLP discovery study. The pivotal study will explore the pharmacokinetics of the InStatin innovative statin inhalant solution's active pharmaceutical ingredient (API) in both lung and systemic blood circulation.
The goal of this pre-clinical research is to provide crucial insights to aid InStatin's team in furthering the development of its advanced therapeutic solution for asthma and chronic obstructive pulmonary disease (COPD). The research will help clarify how to properly target delivery of the solution's active pharmaceutical ingredients (API) in the lungs to enhance the efficacy, bioavailability, and overall treatment outcomes.
"The research efforts between InStatin and Mountain West Research underscores our investment portfolio company's commitment to our vision of 'Transforming Innovation into Wellness" with the pursuit of developing effective asthma and COPD treatments," said Rob Fia, CEO of Therma Bright. "We are confident that the findings from this study will validate the potential of innovative lung delivery systems and their positive impact on patient health."
InStatin continue to push the boundaries of pharmaceutical research in respiratory solutions, and this study marks an important step towards unlocking new possibilities in treatment methodologies. The results are anticipated to play a critical role in guiding the next phases of InStatin's product development in preparation for Phase 1 human trials.
Nova1Advisor's report, as announced in a BioSpace article, projects the Asthma Treatment market size will "hit around USD 39.04 billion by 2032, growing at a CAGR of
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on X.
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as progressing clinical trials at InStatin, and related information as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224191
FAQ
What is the purpose of InStatin's agreement with Mountain West Research?
How does this study benefit InStatin's asthma and COPD treatment development?
What is Therma Bright's (TBRIF) stake in InStatin?
What is the projected market size for Asthma Treatment by 2032?
